Effects of age on biological and functional characterization of adipose‑derived stem cells from patients with end‑stage liver disease

Jin,Yanyu; Yang,Lei; Zhang,Yanyan; Gao,Wei; Yao,Zhi; Song,Yang; Wang,Yuliang

doi:10.3892/mmr.2017.6967

Effects of age on biological and functional characterization of adipose‑derived stem cells from patients with end‑stage liver disease

Authors:
- Yanyu Jin
- Lei Yang
- Yanyan Zhang
- Wei Gao
- Zhi Yao
- Yang Song
- Yuliang Wang
View Affiliations

Affiliations: Department of General Surgery, Tianjin First Central Hospital, Tianjin 300192, P.R. China, Department of Clinical Laboratory Medicine, Tianjin First Central Hospital, Tianjin 300192, P.R. China, National Institute of Health and Medical Research, UMRS 1170, CNRS GDR 3697 Micronit, 94805 Villejuif, France, Organ Transplant Center, Tianjin First Central Hospital, Tianjin 300192, P.R. China, Department of Immunology, Tianjin Medical University, Tianjin 300070, P.R. China, Department of Neurology, Tianjin First Central Hospital, Tianjin 300192, P.R. China
Published online on: July 13, 2017 https://doi.org/10.3892/mmr.2017.6967
Pages: 3510-3518

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adipose‑derived mesenchymal stromal cells (ADSCs) possess a multilineage potential and immunoregulatory properties, and may have great potential in autologous cell‑based technologies. The aim of the present study was to investigate how the age of patients with benign end‑stage liver disease affected the biological and functional characteristics of ADSCs, which is important for increasing the potential effectiveness of autologous cell therapy. ADSCs were obtained and cultured from three distinct age groups: Infant, adult and elderly. Cell immunophenotypic characteristics and antiapoptotic capacity were determined by flow cytometry, and cell proliferation and migration were monitored with a Real‑Time Cell Analyzer. Multilineage differentiation potential was investigated by evaluating the induction response and by reverse transcription‑quantitative polymerase chain reaction. Suppression of T cell proliferation was assessed in a co‑culture system by MTT assay. The regulatory T cells (Tregs) were analyzed by flow cytometry, and ELISAs were performed to detect the cytokine profile in culture supernatants. All ADSC sample phenotypes were characterized as CD90+/CD73+/CD105+/CD45‑/CD34‑, and the apoptotic rate was not statistically different among all ages. However, the proliferation and migratory capacity were significantly increased in infant‑derived ADSCs. In addition, ADSCs derived from infant patients demonstrated a relatively high proclivity for osteogenic differentiation compared with cells derived from either adult or elderly patients. Furthermore, ADSCs co‑cultured with mitogen‑activated T cells significantly suppressed T‑cell proliferation, downregulated the secretion of interferon‑γ and increased the percentage of Tregs, with infant‑derived ADSCs being most effective. Results from the present study indicated that ADSCs derived from infant patients may have biological advantages compared with older cell sources, and may provide an effective reference for the clinical application of ADSCs.

View Figures

View References

1	Lindvig KP, Teisner AS, Kjeldsen J, Strøm T, Toft P, Furhmann V and Krag A: Allocation of patients with liver cirrhosis and organ failure to intensive care: Systematic review and a proposal for clinical practice. World J Gastroenterol. 21:8964–8973. 2015. View Article : Google Scholar : PubMed/NCBI
2	Reddy SS and Civan JM: From child-pugh to model for end-stage liver disease: Deciding who needs a liver transplant. Med Clin North Am. 100:449–464. 2016. View Article : Google Scholar : PubMed/NCBI
3	Lai YH, Duan WD, Yu Q, Ye S, Xiao NJ, Zhang DX, Huang ZQ, Yang ZY and Dong JH: Outcomes of liver transplantation for end-stage biliary disease: A comparative study with end-stage liver disease. World J Gastroenterol. 21:6296–6303. 2015. View Article : Google Scholar : PubMed/NCBI
4	Gong N and Chen X: Partial liver transplantation. Front Med. 5:1–7. 2011. View Article : Google Scholar : PubMed/NCBI
5	Raut V, Alikhanov R, Belghiti J and Uemoto S: Review of the surgical approach to prevent small-for-size syndrome in recipients after left lobe adult LDLT. Surg Today. 44:1189–1196. 2014. View Article : Google Scholar : PubMed/NCBI
6	Nicolas CT, Wang Y and Nyberg SL: Cell therapy in chronic liver disease. Curr Opin Gastroenterol. 32:189–194. 2016.PubMed/NCBI
7	Than NN, Tomlinson CL, Haldar D, King AL, Moore D and Newsome PN: Clinical effectiveness of cell therapies in patients with chronic liver disease and acute-on-chronic liver failure: A systematic review protocol. Syst Rev. 5:1002016. View Article : Google Scholar : PubMed/NCBI
8	Malhotra S, Hu MS, Marshall CD, Leavitt T, Cheung AT, Gonzalez JG, Kaur H, Lorenz HP and Longaker MT: Mesenchymal stromal cells as cell-based therapeutics for wound healing. Stem Cells Int. 2016:41579342016. View Article : Google Scholar : PubMed/NCBI
9	Prockop DJ: Inflammation, fibrosis and modulation of the process by mesenchymal stem/stromal cells. Matrix Biol. 51:7–13. 2016. View Article : Google Scholar : PubMed/NCBI
10	Suk KT, Yoon JH, Kim MY, Kim CW, Kim JK, Park H, Hwang SG, Kim DJ, Lee BS, Lee SH, et al: Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial. Hepatology. 64:2185–2197. 2016. View Article : Google Scholar : PubMed/NCBI
11	Jang YO, Kim YJ, Baik SK, Kim MY, Eom YW, Cho MY, Park HJ, Park SY, Kim BR, Kim JW, et al: Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: A pilot study. Liver Int. 34:33–41. 2014. View Article : Google Scholar : PubMed/NCBI
12	Salama H, Zekri AR, Medhat E, Al Alim SA, Ahmed OS, Bahnassy AA, Lotfy MM, Ahmed R and Musa S: Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease. Stem Cell Res Ther. 5:702014. View Article : Google Scholar : PubMed/NCBI
13	Du Z, Wei C, Yan J, Han B, Zhang M, Peng C and Liu Y: Mesenchymal stem cells overexpressing C-X-C chemokine receptor type 4 improve early liver regeneration of small-for-size liver grafts. Liver Transpl. 19:215–225. 2013. View Article : Google Scholar : PubMed/NCBI
14	Maria AT, Maumus M, Le Quellec A, Jorgensen C, Noël D and Guilpain P: Adipose-derived mesenchymal stem cells in autoimmune disorders: State of the art and perspectives for systemic sclerosis. Clin Rev Allergy Immunol. 52:234–259. 2017. View Article : Google Scholar : PubMed/NCBI
15	Liu T, Mu H, Shen Z, Song Z, Chen X and Wang Y: Autologous adipose tissue-derived mesenchymal stem cells are involved in rat liver regeneration following repeat partial hepatectomy. Mol Med Rep. 13:2053–2059. 2016.PubMed/NCBI
16	Mancini O Kizilay, Shum-Tim D, Stochaj U, Correa JA and Colmegna I: Age, atherosclerosis and type 2 diabetes reduce human mesenchymal stromal cell-mediated T-cell suppression. Stem Cell Res Ther. 6:1402015. View Article : Google Scholar : PubMed/NCBI
17	Wang YL, Li G, Zou XF, Chen XB, Liu T and Shen ZY: Effect of autologous adipose-derived stem cells in renal cold ischemia and reperfusion injury. Transplant Proc. 45:3198–3202. 2013. View Article : Google Scholar : PubMed/NCBI
18	Liu T, Zhang Y, Shen Z, Song Z, Zou X, Chen X, Chen L and Wang Y: Immunomodulatory effects of OX40Ig gene-modified adipose tissue-derived mesenchymal stem cells in rat kidney transplantation. Int J Mol Med. 39:144–152. 2017.PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Wu YE, Du ZR, Cai YM, Peng WG, Zheng GZ, Zheng GL, Wu LB and Li K: Effective expansion of forkhead box P3⁺ regulatory T cells via early secreted antigenic target 6 and antigen 85 complex B from Mycobacterium tuberculosis. Mol Med Rep. 11:3134–3142. 2015.PubMed/NCBI
21	Zhang Z, Lin H, Shi M, Xu R, Fu J, Lv J, Chen L, Lv S, Li Y, Yu S, et al: Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroenterol Hepatol. 27:(Suppl 2). S112–S120. 2012. View Article : Google Scholar
22	Choudhery MS, Badowski M, Muise A, Pierce J and Harris DT: Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation. J Transl Med. 12:82014. View Article : Google Scholar : PubMed/NCBI
23	Harasymiak-Krzyżanowska I, Niedojadło A, Karwat J, Kotuła L, Gil-Kulik P, Sawiuk M and Kocki J: Adipose tissue-derived stem cells show considerable promise for regenerative medicine applications. Cell Mol Biol Lett. 18:479–493. 2013. View Article : Google Scholar : PubMed/NCBI
24	Schneider S, Unger M, van Griensven M and Balmayor ER: Adipose-derived mesenchymal stem cells from liposuction and resected fat are feasible sources for regenerative medicine. Eur J Med Res. 22:172017. View Article : Google Scholar : PubMed/NCBI
25	Efimenko A, Dzhoyashvili N, Kalinina N, Kochegura T, Akchurin R, Tkachuk V and Parfyonova Y: Adipose-derived mesenchymal stromal cells from aged patients with coronary artery disease keep mesenchymal stromal cell properties but exhibit characteristics of aging and have impaired angiogenic potential. Stem Cells Transl Med. 3:32–41. 2014. View Article : Google Scholar : PubMed/NCBI
26	Wu W, Niklason L and Steinbacher DM: The effect of age on human adipose-derived stem cells. Plast Reconstr Surg. 131:27–37. 2013. View Article : Google Scholar : PubMed/NCBI
27	Yarygin KN, Lupatov AY and Kholodenko IV: Cell-based therapies of liver diseases: Age-related challenges. Clin Interv Aging. 10:1909–1924. 2015. View Article : Google Scholar : PubMed/NCBI
28	Cai A, Qiu R, Li L, Zheng D, Dong Y, Yu D, Huang Y, Rao S, Zhou Y and Mai W: Atorvastatin treatment of rats with ischemia-reperfusion injury improves adipose-derivedmesenchymal stem cell migration and survival via the SDF-1α/CXCR-4 axis. PLoS One. 8:e791002013. View Article : Google Scholar : PubMed/NCBI
29	Lai SL, Cheah SC, Wong PF, Noor SM and Mustafa MR: In vitro and in vivo anti-angiogenic activities of Panduratin A. PLoS One. 7:e381032012. View Article : Google Scholar : PubMed/NCBI
30	Ong WK and Sugii S: Adipose-derived stem cells: Fatty potentials for therapy. Int J Biochem Cell Biol. 45:1083–1086. 2013. View Article : Google Scholar : PubMed/NCBI
31	Kornicka K, Marycz K, Tomaszewski KA, Marędziak M and Śmieszek A: The effect of age on osteogenic and adipogenic differentiation potential of human adipose derived stromal stem cells (hASCs) and the impact of stress factors in the course of the differentiation process. Oxid Med Cell Longev. 2015:3091692015. View Article : Google Scholar : PubMed/NCBI
32	Beane OS, Fonseca VC, Cooper LL, Koren G and Darling EM: Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells. PLoS One. 9:e1159632014. View Article : Google Scholar : PubMed/NCBI
33	Sethe S, Scutt A and Stolzing A: Aging of mesenchymal stem cells. Ageing Res Rev. 5:91–116. 2006. View Article : Google Scholar : PubMed/NCBI
34	Owen A and Newsome PN: Mesenchymal stromal cell therapy in liver disease: Opportunities and lessons to be learnt? Am J Physiol Gastrointest Liver Physiol. 309:G791–G800. 2015.PubMed/NCBI
35	Petrou P, Gothelf Y, Argov Z, Gotkine M, Levy YS, Kassis I, Vaknin-Dembinsky A, Ben-Hur T, Offen D, Abramsky O, et al: Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: Results of phase 1/2 and 2a clinical trials. JAMA Neurol. 73:337–344. 2016. View Article : Google Scholar : PubMed/NCBI
36	Mizuno M, Katano H, Otabe K, Komori K, Matsumoto Y, Fujii S, Ozeki N, Tsuji K, Koga H, Muneta T, et al: Platelet-derived growth factor (PDGF)-AA/AB in human serum are potential indicators of the proliferative capacity of human synovial mesenchymal stem cells. Stem Cell Res Ther. 6:2432015. View Article : Google Scholar : PubMed/NCBI
37	Kavanagh DP, Suresh S, Newsome PN, Frampton J and Kalia N: Pretreatment of mesenchymal stem cells manipulates their vasculoprotective potential while not altering their homing within the injured gut. Stem Cells. 33:2785–2797. 2015. View Article : Google Scholar : PubMed/NCBI